Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EZ,
Thanks for memories that this conjures up...
MJ
http://finance.yahoo.com/news/penny-stocks-buy-st-patricks-155400809.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANiOHB2ZjlwYmVscnNiBGcDZFhWcFpEeHVjejQyTkdKaE4yWTNZeTFqWXprNExUTXdNemt0T1RBeVl5MDBObUZoTldOaE4yVTNORFE4Wm1sbGJHUStaV3gwY0E9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA0VMVFA-?.tsrc=applewf
Penny Stocks to Buy on St. Patrick's Day... If You So Choose
CORAL GABLES, FL / ACCESSWIRE / March 17, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. HTBX, CLF, BTU, and ELTP have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
Elite Pharmaceuticals, Inc. (ELTP) announced Thursday (3/17) that the New Drug Application for SequestOXTM (ELI-200), Elite's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate, has been accepted and granted priority review by the United States Food and Drug Administration. SequestOxTM is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone which incorporates 5 mg, 10 mg, 15 mg, 20 mg and 30 mg doses of oxycodone into capsules. After this announcement, shares of ELTP increased from a previous close on Wednesday (3/16) of 0.2995 to highs on St. Patrick's Day of 0.3598.
Hate to burst your bubble, Stockboy... But the facts are your bet was "we see low .20's". Today's dip to $.2914 is nowhere near the low $.20's:
Elite's management will host a conference call to discuss the results of operations and provide an update on recent business developments. Company executives will conduct a question and answer session following their remarks.
Date: Wednesday, February 10, 2016 Time: 11:30 AM EST
Dial-in numbers:
1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. Here is a suggested list of questions:
1. Any plans for ELI-154?
2. Now that the NDA filing will be accepted soon, what are the status updates on ELI 201 and 202? Has the FDA given any indication (or have they been asked) about reduced trial requirements for ELI products that are similar to ELI 200? HAL studies and Phase 3s required for every single product?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Are there any numbers yet on the sales of Isradpin?
6. Status update on the arbitration of Phentermine with Precision Dose?
7. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
8. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
9. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
10. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
11. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
12. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
13. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
14. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
15. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable? ?
16. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
17. Regarding EPIC's Oxycodone Generic. Is it strictly EPIC's ANDA product? Did Elite help to develop EPIC's Oxycodone?
18. Is Elite going to apply for a research grant for continuing and future applications?
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Now that the NDA filing will be accepted soon, what are the status updates on ELI 201 and 202? Has the FDA given any indication (or have they been asked) about reduced trial requirements for ELI products that are similar to ELI 200? HAL studies and Phase 3s required for every single product?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Are there any numbers yet on the sales of Isradpin?
6. Status update on the arbitration of Phentermine with Precision Dose?
7. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
8. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
9. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
10. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
11. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
12. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
13. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
14. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
15. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable? ?
16. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
17. Regarding EPIC's Oxycodone Generic. Is it strictly EPIC's ANDA product? Did Elite help to develop EPIC's Oxycodone?
18. Is Elite going to apply for a research grant for continuing and future applications?
19. Given the size of Elite and the necessity for additional marketing & sales force for additional ADT products beyond what Epic can provide for ELI 200, what is Elite's current plan for obtaining additional partnerships and how is that plan shaping up?
20. Elite has a generic run rate of $10-14 million presently. Can we start getting forward guidance?... It would help increase Elite's visibility.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Now that the NDA filing will be accepted soon, what are the status updates on ELI 201 and 202? Has the FDA given any indication (or have they been asked) about reduced trial requirements for ELI products that are similar to ELI 200? HAL studies and Phase 3s required for every single product?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Are there any numbers yet on the sales of Isradpin?
6. Status update on the arbitration of Phentermine with Precision Dose?
7. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
8. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
9. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
10. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
11. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
12. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
13. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
14. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
15. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable? ?
16. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
17. Regarding EPIC's Oxycodone Generic. Is it strictly EPIC's ANDA product? Did Elite help to develop EPIC's Oxycodone?
18. Is Elite going to apply for a research grant for continuing and future applications?
19. Given the size of Elite and the necessity for additional marketing & sales force for additional ADT products beyond what Epic can provide for ELI 200, what is Elite's current plan for obtaining additional partnerships and how is that plan shaping up?
20. Elite has a generic run rate of $10-14 million presently. Can we start getting forward guidance?... It would help increase Elite's visibility.
The list isn't done yet... We've got until next week for more questions to get added to the list. Especially, after the 10Q is out.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Now that the NDA filing will be accepted soon, what are the status updates on ELI 201 and 202? Has the FDA given any indication (or have they been asked) about reduced trial requirements for ELI products that are similar to ELI 200? HAL studies and Phase 3s required for every single product?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Are there any numbers yet on the sales of Isradpin?
6. Status update on the arbitration of Phentermine with Precision Dose?
7. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
8. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
9. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
10. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
11. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
12. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
13. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
14. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
15. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable? ?
16. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
17. Regarding EPIC's Oxycodone Generic. Is it strictly EPIC's ANDA product? Did Elite help to develop EPIC's Oxycodone?
18. Is Elite going to apply for a research grant for continuing and future applications?
19.
Fellow ELTP Investors,
Since indications are that ELTP could hold its Conference Call next week, I'd like to once again facilitate the collection of shareholder input for the Q&A session with ELTP management.
For those who have not participated in ELTP's Q&A session before, I'll repeat the purpose/intent of putting together the question list. Due to time constraints, callers who participate in the Q&A session are limited to asking one question. We’ve got some very knowledgeable shareholders here on iHub who are well versed in the pharmaceutical sector and can provide excellent questions. But they may not be available for the Conference Call or, if they do partake, will be allotted one question to ask. That’s where the rest of us come in. By referring to the Conference Call Question List, we can collectively get most, if not all, of the questions asked.
I will kickoff the list with leftover questions from the previous Conference Call that were either not asked or are still relevant for updates. I've also added a question that was suggested on this Board recently.
Please note that my role is NOT to censor or editorialize submitted questions. If you have an opinion on what should or should not be asked at the Q&A session, then please voice it via a public post on this board. Of course, it's ultimately each callers' prerogative as to what they choose to ask with their allotted question.
With that being said, the Conference Call Question list will follow.
MJ
I recall there were only about 3 shareholders (counting me) who made the New York City meeting.
I believe so... I went to most, if not all, of the shareholder meetings in Hartcourt's hayday... Kissimmee, Long Beach, Las Vegas and New York City. Not necessarily in that order. I'll take a picture of the hat and will post it here.
I recall Phan gave the baseball caps at the Shareholders meeting that was held in Kissimmee, FL.
Did you lose your Harcourt baseball cap? Still got mine!
Gman,
It would be tough to reach a consensus from the iHub board on the top 6 questions. The purpose of the Q&A list is to provide a repository of questions for those who call-in. Historically, very few from the Q&A list get asked as callers probably are either not iHub members or, if they are members, choose to do their own thing.
MJ
But...But...But... What about when you said this?:
Done...
ELTP made iHub's Top 10 Active Stock Market Forums today.
Kentucky settles lawsuit with Purdue Pharma, maker of OxyContin, for $24 million
www.foxnews.com/us/2015/12/23/kentucky-settles-lawsuit-with-purdue-pharma-maker-oxycontin-for-24-million.html
FRANKFORT, Ky. – Kentucky Attorney General Jack Conway has settled a lawsuit against the manufacturer of OxyContin for $24 million.
The state first filed the lawsuit back in 2007. It accused Purdue Pharma of marketing the prescription painkiller as nonaddictive because it slowly released the drug over 12 hours. But if the pill was crushed, it lost its time release qualities and created an instant high.
Kentucky officials said that led to a wave of addiction and increased medical costs across the state. Purdue Pharma replaced the drug with a new version in 2010.
The agreement says Purdue Pharma will pay Kentucky $12 million followed by another $12 million over the next eight years. The court ordered Kentucky to spend the money on addiction treatment programs.
Purdue Pharma did not admit any wrongdoing.
There's an excellent pps forecast analysis in iHub's Info section for ELTP that was done by AJSails based on potential market share.
That's right down the street from where I work. I just might check it out if ELTP is there...
What is truly notorious for misinformation are predictions of a 2 cent ELTP share price.